Grants paid by The Adenoid Cystic Carcinoma Research Foundation
EIN 20-6745475 · Needham, MA · Form 990, Schedule I · NTEE H12
The Adenoid Cystic Carcinoma Research Foundation of Needham, MA (EIN 20-6745475) reported 50 grants paid totaling $3,374,637 to 26 recipients in tax years 2018–2024, on Form 990, Schedule I. Derived from IRS e-file data, dataset version 2026.09.0, built 2026-09-03.
Grants paid
$3,374,637
50 grants
Recipients
26
distinct organizations
Tax years
2018–2024
7 filings in the corpus
By tax year
| Tax year | Grants paid | Amount paid | Approved for future |
|---|---|---|---|
| 2018 | 6 | $617,115 | — |
| 2019 | 10 | $636,654 | — |
| 2020 | 10 | $619,981 | — |
| 2021 | 5 | $439,967 | — |
| 2022 | 7 | $467,712 | — |
| 2023 | 4 | $175,883 | — |
| 2024 | 8 | $417,325 | — |
Top recipients
The 26 recipients receiving the most from The Adenoid Cystic Carcinoma Research Foundation, by grants paid, out of 26 distinct recipients.
| Recipient | Match | Location | Grants | Total paid | Latest year |
|---|---|---|---|---|---|
| Dana-Farber Cancer Institute 04-2263040 | A | Boston, MA | 8 | $651,328 | 2024 |
| University of Chicago 36-2177139 | A | Chicago, IL | 3 | $562,017 | 2022 |
| M D Anderson Cancer Center 74-6001118 | A | Houston, TX | 8 | $492,471 | 2024 |
| University of New Mexico 85-6000642 | A | Albuquerque, NM | 3 | $245,097 | 2021 |
| Columbia University 13-5598093 | A | New York, NY | 1 | $200,000 | 2018 |
| Harvard Medical School 04-2103580 | A | Boston, MA | 1 | $200,000 | 2019 |
| Massachusetts Institute of Technology 04-2103594 | A | Cambridge, MA | 2 | $139,486 | 2019 |
| Mission Viejo Hospital and UCLA 95-6006143 | A | Mission Viejo, CA | 1 | $100,000 | 2024 |
| John Hopkins University 52-0595110 | A | Baltimore, MD | 1 | $100,000 | 2022 |
| University of Pennsylvania 23-1352685 | A | Philadelphia, PA | 1 | $75,000 | 2023 |
| Massachusetts Eye and Ear Infirmary 04-2103591 | A | Boston, MA | 2 | $72,557 | 2020 |
| Mass General 04-3230035 | A | Boston, MA | 1 | $50,000 | 2024 |
| H Lee Moffitt Cancer Center & Research Institute Inc 59-2451713 | A | Tampa, FL | 1 | $49,999 | 2024 |
| Virgina Commonwealth University of Medicine 54-6001758 | A | Richmond, VA | 1 | $49,989 | 2024 |
| Brigham and Women's Hospital 90-0656139 | A | Boston, MA | 2 | $49,112 | 2020 |
| University of Michigan 38-6006309 | A | Ann Arbor, MI | 2 | $45,258 | 2020 |
| Johns Hopkins University 52-0591656 | A | Baltimore, MD | 2 | $37,500 | 2020 |
| The Mount Sinai Hospital 13-1624096 | A | New York, NY | 2 | $37,486 | 2020 |
| Baylor College of Medicine 74-1613878 | A | Houston, TX | 1 | $36,768 | 2024 |
| Rutgers Cancer Institute 22-6001086 | A | New Brunswick, NJ | 1 | $30,569 | 2024 |
| The Broad Institute Inc 26-3428781 | A | Cambridge, MA | 1 | $25,000 | 2019 |
| Massachusetts General Hospital 04-1564655 | A | Boston, MA | 1 | $25,000 | 2022 |
| University of Tennessee Health Science Center 62-6001636 | A | Memphis, TN | 1 | $25,000 | 2020 |
| Mission Hospital - Mission Viejo 95-1643360 | A | Mission Viejo, CA | 1 | $25,000 | 2019 |
| University of Miami 59-2579805 | A | Coral Gables, FL | 1 | $25,000 | 2020 |
| Mount Sinai School of Medicine 13-6171197 | A | New York, NY | 1 | $25,000 | 2023 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Every grant
All 50 grant rows this organization reported, most recent first.
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2024 | Mission Viejo Hospital and UCLA Mission Viejo, CA | A | $100,000 | paid | CT-GUIDED LDR BRACHYTHERAPY FOR ADENOID CYSTIC CARCINOMA LUNG METASTASES: EFFICACY AND SAFETY OUTCOMES. | 202521339349303087 |
| 2024 | Mass General Boston, MA | A | $50,000 | paid | CHEMICAL PROTEOMICS TO TARGET MYB IN ACC | 202521339349303087 |
| 2024 | Md Anderson Cancer Center Houston, TX | A | $50,000 | paid | VEGFR INHIBITORS IN ADENOID CYSTIC CARCINOMA | 202521339349303087 |
| 2024 | Dana Farber Cancer Institute Boston, MA | A | $50,000 | paid | STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR EARLY TREATMENT OF OLIGOMETASTATIC ADENOID CYSTIC CARCINOMA: THE SOLAR TRIAL | 202521339349303087 |
| 2024 | H Lee Moffitt Cancer Center & Research Institute Inc Tampa, FL | A | $49,999 | paid | MOLECULAR CHARACTERIZATION OF THE SALIVARY ADENOID CYSTIC CARCINOMA TUMOR IMMUNE LANDSCAPE BY ANATOMIC SUBSITE | 202521339349303087 |
| 2024 | Virgina Commonwealth University of Medicine Richmond, VA | A | $49,989 | paid | TO STUDY THE EXPRESSION OF FLOWER-WIN AND FLOWER-LOSE IN ADENOID CYSTIC CARCINOMA (ACC) | 202521339349303087 |
| 2024 | Baylor College of Medicine Houston, TX | A | $36,768 | paid | ADENOID CYSTIC CARCINOMA ARISING AT NON-SALIVARY SITES IN THE U.S.- A PROPOSAL FOR ANALYSIS OF TWO NATIONAL CANCER DATASETS. | 202521339349303087 |
| 2024 | Rutgers Cancer Institute New Brunswick, NJ | A | $30,569 | paid | PATTERNS OF CARE IN THE MANAGEMENT OF PATIENTS WITH ADENOID CYSTIC CARCINOMA OF THE BREAST | 202521339349303087 |
| 2023 | University of Pennsylvania Philadelphia, PA | A | $75,000 | paid | ENHANCING IMMUNO-ONCOLOGY STRATEGIES FOR ADENOID CYSTIC CARCINOMA THROUGH PRECISE TARGETING OF CELL SURFACE PROTEINS | 202401319349303220 |
| 2023 | Md Anderson Cancer Center Houston, TX | A | $50,900 | paid | SUPPORT FOR THE STUDY OF ORGANOID DEVELOPMENT AND INTEGRATED GENOMIC CHARACTERIZATION OF ACC | 202401319349303220 |
| 2023 | Mount Sinai School of Medicine New York, NY | A | $25,000 | paid | ASSESSING THE NEURAL TUMOR MICROENVIRONMENT OF ADENOID CYSTIC CARCINOMA | 202401319349303220 |
| 2023 | Dana Farber Cancer Institute Boston, MA | A | $24,983 | paid | TISSUE-INFORMED CELL-FREE DNA METHYLATION ANALYSIS TO DETECT ADENOID CYSTIC CARCINOMA | 202401319349303220 |
| 2022 | Dana-Farber Boston, MA | A | $242,712 | paid | SUPPORT FOR THE STUDY OF TARGETED PROTEIN DEGRADATION APPROACHES TO DEFINE THE MOLECULAR MECHANISMS OF MYB ONCOPROTEINS IN ACC | 202341349349300099 |
| 2022 | John Hopkins University Baltimore, MD | A | $100,000 | paid | SUPPORT FOR A PHASE 2, SINGLE-ARM, MULTI-CENTER STUDY OF 177LU-PSMA (177LU-PNT2002) IN PATIENTS WITH PSMA-POSITIVE ADENOID CYSTIC CARCINOMA | 202341349349300099 |
| 2022 | University of Chicago Chicago, IL | A | $25,000 | paid | SUPPORT FOR THE STUDY OF ORGANOID DEVELOPMENT AND INTEGRATED GENOMIC CHARACTERIZATION OF ACC | 202341349349300099 |
| 2022 | Md Anderson Cancer Center Houston, TX | A | $25,000 | paid | SUPPORT FOR THE STUDY OF IMAGING FEATURES AND NATURAL HISTORY OF METASTATIC ADENOID CYSTIC CARCINOMA | 202341349349300099 |
| 2022 | Dana-Farber Boston, MA | A | $25,000 | paid | SUPPORT FOR THE STUDY OF DIRECT GENE-REGULATORY FUNCTIONS OF MYB/MYBL1 FUSION ONCOPROTEINS | 202341349349300099 |
| 2022 | Dana-Farber Boston, MA | A | $25,000 | paid | SUPPORT FOR THERAPEUTIC DRUG SCREENING USING A NOVEL IMPLANTABLE MICRODEVICE (IMD) IN ADENOID CYSTICCARCINOMA (ACC): A WINDOW OF OPPORTUNITY STUDY | 202341349349300099 |
| 2022 | Massachusetts General Hospital Boston, MA | A | $25,000 | paid | SUPPORT FOR MGH ACC CLINICAL DATABASE | 202341349349300099 |
| 2021 | Dana Farber Boston, MA | A | $233,633 | paid | SUPPORT FOR THE STUDY STEREOTACTIC BODY RADIOTHERAPY (SBRT) FOR EARLY TREATMENT OF OLIGOMETASTATIC ADENOID CYSTIC CARCINOMA: THE SOLAR TRIAL | 202201369349307550 |
| 2021 | M D Anderson Cancer Center Houston, TX | A | $131,572 | paid | SUPPORT FOR THE STUDY AL101 PRIOR TO STANDARD-OF-CARE SURGERY IN PATIENTS WITH NOTCH ACTIVATED ADENOID CYSTIC CARCINOMA | 202201369349307550 |
| 2021 | Dana Farber Boston, MA | A | $25,000 | paid | SUPPORT THE STUDY OF EVALUATING COMBINATION TARGETED THERAPY FOR PATIENTS WITH VEGFR-REFRACTORY ADVANCED ADENOID CYSTIC CARCINOMA (ACC) USING EX VIVO PATIENT DERIVED CELL LINES (PDCL) | 202201369349307550 |
| 2021 | M D Anderson Cancer Center Houston, TX | A | $25,000 | paid | SUPPORT FOR THE STUDY IMAGING FEATURES AND NATURAL HISTORY OF METASTATIC ADENOID CYSTIC CARCINOMA | 202201369349307550 |
| 2021 | University of New Mexico Albuquerque, NM | A | $24,762 | paid | SUPPORT FOR THE STUDY OF ACCRF BIOINFORMATICS PROJECT | 202201369349307550 |
| 2020 | University of Chicago Chicago, IL | A | $317,017 | paid | SUPPORT FOR THE STUDY OF ORGANOID DEVELOPMENT AND INTEGRATED GENOMIC CHARACTERIZATION OF ACC | 202121349349302482 |
| 2020 | University of New Mexico Albuquerque, NM | A | $82,706 | paid | SUPPORT FOR THE STUDY OF BIOMARKER FOR ACC OUTCOME | 202121349349302482 |
| 2020 | M D Anderson Cancer Center Houston, TX | A | $50,000 | paid | SUPPORT FOR THE STUDY OF ACC MICROENVIRONMENT AND SPATIAL ANALYSIS USING IMAGING MASS CYTOMETRY,DEVELOPMENT OF CIRCULATING EXTRACELLULAR VESICLES AS AN EARLY BIOMARKER IN PATIENTS WITH ACC | 202121349349302482 |
| 2020 | Massachusetts Eye and Ear Infirmary Boston, MA | A | $25,000 | paid | SUPPORT FOR THE ROLE OF YAP/TEAD AND P63 NETWORK IN ACC | 202121349349302482 |
| 2020 | Johns Hopkins University Baltimore, MD | A | $25,000 | paid | SUPPORT FOR THE STUDY OF MOLECULAR VALIDATION OF ANIN VIVOMODEL FOR ACC | 202121349349302482 |
| 2020 | Brigham and Women's Hospital Boston, MA | A | $25,000 | paid | SUPPORT FOR THE STUDY OF DEVELOPING MODEL SYSTEMS TO DETERMINE THE MECHANISMS AND DIRECT DOWNSTREAM EFFECTS OF NOTCH SIGNALING IN ACC | 202121349349302482 |
| 2020 | The Mount Sinai Hospital New York, NY | A | $25,000 | paid | SUPPORT FOR THE STUDY OF MODELING METASTATIC DISSEMINATION OF ADENOID CYSTIC CARCINOMAIN VIVO | 202121349349302482 |
| 2020 | University of Tennessee Health Science Center Memphis, TN | A | $25,000 | paid | SUPPORT FOR THE STUDY OF TARGETING T CELL RESPONSE IN ACC | 202121349349302482 |
| 2020 | University of Miami Coral Gables, FL | A | $25,000 | paid | SUPPORT FOR THE STUDY OF MOLECULAR SURVEILLANCE OF ACC | 202121349349302482 |
| 2020 | University of Michigan Ann Arbor, MI | A | $20,258 | paid | SUPPORT FOR THE STUDY OF CHARACTERIZATION OF NOVEL TISSUE BIOMARKERS IN ACC | 202121349349302482 |
| 2019 | University of Chicago Chicago, IL | A | $220,000 | paid | SUPPORT FOR THE STUDY OF DEEP NEURAL NETWORK DEVELOPMENT FOR ACC | 202031849349301918 |
| 2019 | Harvard Medical School Boston, MA | A | $200,000 | paid | SUPPORT FOR THE STUDY OF THE EFFICACY OF RETINOIC ACID IN TARGETING MYB AND TREATING PATIENTS WITH ACC | 202031849349301918 |
| 2019 | M D Anderson Cancer Center Houston, TX | A | $59,999 | paid | SUPPORT FOR WHOLE EXOME SEQUENCING FOR LACRIMAL GLAND ACC, IMMUNE MICROENVIRONMENT AND MICROBIOME IN ACC, AND CELL LINE BANKING | 202031849349301918 |
| 2019 | Massachusetts Eye and Ear Infirmary Boston, MA | A | $47,557 | paid | SUPPORT FOR THE CLINICAL VALIDATION OF AN FNA PROGRAM FOR MOLECULARLY-INFORMED DECISION MAKING; COMPARATIVE ANALYSIS OF SIX DIFFERENT ANTIBODIES TO DETECT MYB AND MYB11 EXPRESSION IN ACC BY IMMUNOHISTOCHEMISTRY. | 202031849349301918 |
| 2019 | The Broad Institute Inc Cambridge, MA | A | $25,000 | paid | SUPPORT FOR THE CREATION OF AN ACC DEPENDENCY MAP | 202031849349301918 |
| 2019 | Mission Hospital - Mission Viejo Mission Viejo, CA | A | $25,000 | paid | SUPPORT FOR STUDY OF CT GUIDED PALLADIUM103 SEED BRACHYTHERAPY FOR METASTATIC ACC: A RETROSPECTIVE REVIEW OF CLINICAL OUTCOMES AND TUMOR VOLUME AS ASSESSED ON CT. | 202031849349301918 |
| 2019 | Brigham and Women's Hospital Boston, MA | A | $24,112 | paid | SUPPORT FOR THE STUDY OF BCL2 FAMILY MEMBER EXPRESSION IN ACC | 202031849349301918 |
| 2019 | Johns Hopkins University Baltimore, MD | A | $12,500 | paid | SUPPORT FOR THE STUDY OF ALTERNATIVE PATIENT DERIVED XENOGRAFT IN VIVO MODEL FOR ACC | 202031849349301918 |
| 2019 | The Mount Sinai Hospital New York, NY | A | $12,486 | paid | SUPPORT FOR THE STUDY OF ALTERNATIVE PATIENT DERIVED XENOGRAFT IN VIVO MODEL FOR ACC | 202031849349301918 |
| 2019 | Massachusetts Institute of Technology Cambridge, MA | A | $10,000 | paid | SUPPORT FOR ADVANCING MYB SMALL MOLECULE BINDERS | 202031849349301918 |
| 2018 | Columbia University New York, NY | A | $200,000 | paid | SUPPORT FOR THE STUDY OF USING "SINGLE-CELL GENOMICS" TO DE-CONVOLUTE THE CELL COMPOSITION OF ACCS AND GUIDE THE DESIGN OF NOVEL ANTI-TUMOR DRUG COMBINATIONS. | 201901309349303070 |
| 2018 | University of New Mexico Albuquerque, NM | A | $137,629 | paid | SUPPORT FOR THE STUDY OF RNASEQ SUBGROUPS | 201901309349303070 |
| 2018 | Massachusetts Institute of Technology Cambridge, MA | A | $129,486 | paid | SUPPORT FOR ADVANCING MYB SMALL MOLECULE BINDERS | 201901309349303070 |
| 2018 | M D Anderson Cancer Center Houston, TX | A | $100,000 | paid | SUPPORT FOR TRANSGENIC MOUSE MODEL FOR SALIVARY ACC AND CELL LINE BANKING | 201901309349303070 |
| 2018 | Dana-Farber Cancer Institute Boston, MA | A | $25,000 | paid | SUPPORT FOR STUDY OF PEMBRO/RT CORRELATIVES | 201901309349303070 |
| 2018 | University of Michigan Ann Arbor, MI | A | $25,000 | paid | SUPPORT FOR THE STUDY OF ENTINOSTAT AND CISPLATIN | 201901309349303070 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Source filings
Every figure above is traceable to one of these IRS e-file returns by its OBJECT_ID.
| Form | Tax year | Period end | Filed | Schema | IRS OBJECT_ID |
|---|---|---|---|---|---|
| 990 | 2024 | 2024-12-31 | not stated | 2024v5.1 | 202521339349303087 |
| 990 | 2023 | 2023-12-31 | not stated | 2023v5.0 | 202401319349303220 |
| 990 | 2022 | 2022-12-31 | not stated | 2022v5.0 | 202341349349300099 |
| 990 | 2021 | 2021-12-31 | not stated | 2021v4.2 | 202201369349307550 |
| 990 | 2020 | 2020-12-31 | not stated | 2020v4.1 | 202121349349302482 |
| 990 | 2019 | 2019-12-31 | not stated | 2019v5.1 | 202031849349301918 |
| 990 | 2018 | 2018-12-31 | not stated | 2018v3.1 | 201901309349303070 |
Derived from IRS Form 990 e-file XML; recipient identities from the IRS Exempt Organizations Business Master File. Dataset version 2026.09.0, built 2026-09-03. The same rows as Parquet: manifest; as JSON: /api/funders/206745475.json.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.